Overview
- Tango reported on Monday that 11 of 12 evaluable patients with MTAP‑deleted, RAS‑mutant metastatic pancreatic ductal adenocarcinoma responded to vopimetostat plus daraxonrasib, yielding a 92% objective response rate, 100% disease control and 90% progression‑free rate at six months.
- The company described the combination as generally well tolerated with mostly grade 1–2 side effects, two dose‑limiting toxicities at the higher vopimetostat dose, and no treatment‑related grade 4–5 events or discontinuations.
- Tango said it will move the regimen toward a randomized phase 3 trial for first‑line MTAP‑deleted PDAC and expects to finalize the trial design in the second half of 2026 pending regulatory discussions.
- The results build on daraxonrasib’s recent phase 3 monotherapy success, which reportedly doubled overall and progression‑free survival versus chemotherapy and has created regulatory momentum for RAS‑directed therapies.
- Key caveats are the small cohort (12 evaluable PDAC patients at cutoff), short follow‑up and operational issues for broader use, and MTAP deletions—present in roughly 40% of pancreatic cancers—will shape who could benefit if later trials confirm these early results.